• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Comstock And 2 Other Stocks Under $2 Insiders Are Buying

    5/29/24 8:34:11 AM ET
    $LODE
    $VERU
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LODE alert in real time by email

    The Dow Jones index closed lower by over 200 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

    Comstock

    • The Trade: Comstock Inc. (NYSE:LODE) Chief Engineering Officer Rahul Bobbili bought a total of 25,000 shares at an average price of $0.25. To acquire these shares, it cost around $6,350.
    • What's Happening: Comstock, on May 17, announced a private placement of 1.25 million restricted shares at $0.40/share to the Chairman & CEO.
    • What Comstock Does: Comstock Inc is engaged in technologies that efficiently use wasted and under-utilized natural resources to produce renewable energy and other products that contribute to balancing uses and emissions of carbon and enhance mineral and material discoveries.

    Veru

    • The Trade: Veru Inc. (NASDAQ:VERU) Director, Chief Corporate Officer Harry Fisch acquired a total of 4,000 shares at an average price of $1.25. To acquire these shares, it cost around $5,000..
    • What's Happening: On May 8, Veru posted a wider-than-expected quarterly loss.
    • What Veru Does: Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS).

    Tecogen

    • The Trade: Tecogen Inc. (OTC:TGEN) Director John Hatsopoulos acquired a total of 11,935 shares at an average price of $0.80. The insider spent around $9,516 to buy those shares.
    • What's Happening: On May 8, Tecogen reported revenues of $6.2 million and net loss of $1.1 million for the quarter ended March 31.
    • What Tecogen Does: Tecogen Inc, designs, manufactures, markets, and maintains high-efficiency, ultra-clean cogeneration products.

    Now Read This: Advance Auto Parts, Ooma And 3 Stocks To Watch Heading Into Wednesday

    Get the next $LODE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LODE
    $VERU

    CompanyDatePrice TargetRatingAnalyst
    Veru Inc.
    $VERU
    12/18/2025$25.00Buy
    Canaccord Genuity
    Comstock Inc.
    $LODE
    11/4/2025Market Perform → Outperform
    Noble Capital Markets
    Comstock Inc.
    $LODE
    8/18/2025$4.00Buy → Neutral
    Ladenburg Thalmann
    Comstock Inc.
    $LODE
    7/29/2025$12.00Buy
    Ladenburg Thalmann
    Comstock Inc.
    $LODE
    12/18/2024Outperform → Market Perform
    Noble Capital Markets
    Veru Inc.
    $VERU
    5/14/2024$5.00Buy
    B. Riley Securities
    Veru Inc.
    $VERU
    3/28/2024$3.00Outperform
    Raymond James
    Veru Inc.
    $VERU
    6/7/2023$1.00Underperform → Hold
    Jefferies
    More analyst ratings

    $LODE
    $VERU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Comstock Inc. Featured on Water Tower Research Small-Cap Spotlight Podcast

    VIRGINIA CITY, Nev., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE:LODE) ("Comstock" or the "Company") and its subsidiary, Comstock Metals LLC ("Comstock Metals"), a leader in the responsible recycling of end-of-life solar panels and the only certified, zero-landfill solar recycling solution in North America, today announced that Executive Chairman and Chief Executive Officer Corrado De Gasperis was featured on the Water Tower Research Small-Cap Spotlight Podcast. The Small-Cap Spotlight Podcast explores a deeper analysis of the end-of-life solar panel dilemma and the innovations required to both handle millions and millions of end-of-life panels in an environmentally safe and eff

    2/11/26 8:10:49 AM ET
    $LODE
    Major Chemicals
    Industrials

    Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

    -- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2026 first quarter ended December 31, 2025, and provided a corporate update. "The strategy for the next generation of obesity drugs should be a combination therapy with GLP-1 receptor agonists for

    2/11/26 6:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Comstock Metals Awarded Tax Abatement From the Nevada Governor's Office of Economic Development

    VIRGINIA CITY, Nevada, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE:LODE) ("Comstock" and the "Company") and its subsidiary, Comstock Metals LLC ("Comstock Metals"), a leader in the responsible recycling of end-of-life solar panels and the only certified, zero-landfill solar recycling solution in North America, today announced that it has received tax abatements from the Nevada Governor's Office of Economic Development ("GOED"). GOED awarded approximately $900,000 in tax abatements that will apply to Comstock Metals' first-of-its-kind zero-landfill, solar panel recycling and critical metal production facility that is scheduled to commence production in the second quarter of 2026,

    2/9/26 6:15:00 AM ET
    $LODE
    Major Chemicals
    Industrials

    $LODE
    $VERU
    SEC Filings

    View All

    SEC Form 10-Q filed by Veru Inc.

    10-Q - VERU INC. (0000863894) (Filer)

    2/11/26 10:32:14 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - VERU INC. (0000863894) (Filer)

    2/11/26 7:00:14 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Comstock Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Comstock Inc. (0001120970) (Filer)

    2/3/26 4:30:28 PM ET
    $LODE
    Major Chemicals
    Industrials

    $LODE
    $VERU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salinas Mayaguez J was granted 89,262 shares, increasing direct ownership by 20,104% to 89,706 units (SEC Form 4)

    4 - Comstock Inc. (0001120970) (Issuer)

    1/6/26 7:02:00 PM ET
    $LODE
    Major Chemicals
    Industrials

    Director Drozdoff Leo M was granted 90,481 shares, increasing direct ownership by 151% to 150,481 units (SEC Form 4)

    4 - Comstock Inc. (0001120970) (Issuer)

    1/6/26 7:01:35 PM ET
    $LODE
    Major Chemicals
    Industrials

    Director Nance William John was granted 90,481 shares, increasing direct ownership by 390% to 113,681 units (SEC Form 4)

    4 - Comstock Inc. (0001120970) (Issuer)

    1/6/26 7:01:10 PM ET
    $LODE
    Major Chemicals
    Industrials

    $LODE
    $VERU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rankowitz Michael L bought $84,351 worth of shares (150,000 units at $0.56), increasing direct ownership by 150% to 250,000 units (SEC Form 4)

    4 - VERU INC. (0000863894) (Issuer)

    2/20/25 10:00:11 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Drozdoff Leo M bought $29,200 worth of shares (200,000 units at $0.15), increasing direct ownership by 50% to 600,000 units (SEC Form 4)

    4 - Comstock Inc. (0001120970) (Issuer)

    8/14/24 5:05:01 PM ET
    $LODE
    Major Chemicals
    Industrials

    Bobbili Rahul bought $6,350 worth of shares (25,000 units at $0.25), increasing direct ownership by 2% to 1,100,000 units (SEC Form 4)

    4 - Comstock Inc. (0001120970) (Issuer)

    5/28/24 6:22:24 PM ET
    $LODE
    Major Chemicals
    Industrials

    $LODE
    $VERU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ENTADFI issued to VERU INC

    Submission status for VERU INC's drug ENTADFI (ORIG-1) with active ingredient FINASTERIDE;TADALAFIL has changed to 'Approval' on 12/09/2021. Application Category: NDA, Application Number: 215423, Application Classification: Type 4 - New Combination

    12/13/21 8:12:46 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LODE
    $VERU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Veru with a new price target

    Canaccord Genuity initiated coverage of Veru with a rating of Buy and set a new price target of $25.00

    12/18/25 9:11:57 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Comstock upgraded by Noble Capital Markets

    Noble Capital Markets upgraded Comstock from Market Perform to Outperform

    11/4/25 9:31:52 AM ET
    $LODE
    Major Chemicals
    Industrials

    Comstock downgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann downgraded Comstock from Buy to Neutral and set a new price target of $4.00

    8/18/25 8:47:58 AM ET
    $LODE
    Major Chemicals
    Industrials

    $LODE
    $VERU
    Leadership Updates

    Live Leadership Updates

    View All

    Comstock Set to Join Russell Microcap® Index

    VIRGINIA CITY, Nev., June 30, 2025 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE:LODE) ("Comstock" and the "Company") announced today that it is set to join the Russell Microcap® Index at the conclusion of the 2025 Russell Microcap Index's annual reconstitution, effective after the U.S. market opens on June 30, 2025. Membership in the Russell Microcap Index means automatic inclusion in the appropriate growth and value indexes. FTSE Russell determines membership for its indices primarily by objective, market-capitalization rankings and style attributes. "Our representation in the Russell Microcap Index independently recognizes our progress and growing value and positions our already appreciating

    6/30/25 6:00:00 AM ET
    $LODE
    Major Chemicals
    Industrials

    Comstock Announces Appointment of Chief Financial Officer

    VIRGINIA CITY, Nev., May 15, 2025 (GLOBE NEWSWIRE) -- Comstock Inc. (the "Company") today announced that the Board of Directors has approved the appointment of Mr. Judd B. Merrill, as Chief Financial Officer of the Company and President of the Company's wholly-owned mining subsidiary, Comstock Mining LLC, that, together with the Company's other affiliated mining activities, controls all of the Company's mineral exploration and mining assets. Mr. Merrill will assume his new role starting May 19, 2025. Mr. Merrill brings extensive public company mining and clean mineral technology industry experience to Comstock. Mr. Merrill, age 54, most recently served as Chief Financial Officer of Aqua M

    5/15/25 4:15:00 PM ET
    $AQMS
    $LODE
    Metal Fabrications
    Industrials
    Major Chemicals

    Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board

    MIAMI, FL, June 01, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced the appointment of Erik Swenson, M.D., a world-renowned pulmonologist specializing in critical care, and Robert Schooley, M.D., an accomplished infectious disease physician and researcher, to its Infectious Disease Scientific Advisory Board (SAB) to join David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, who is Chairman of the SAB. "We are pleased to share that Dr. Erik Swenson and

    6/1/23 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LODE
    $VERU
    Financials

    Live finance-specific insights

    View All

    Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

    -- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2026 first quarter ended December 31, 2025, and provided a corporate update. "The strategy for the next generation of obesity drugs should be a combination therapy with GLP-1 receptor agonists for

    2/11/26 6:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

    MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, February 11, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 first quarter financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru I

    2/4/26 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru to Report Fiscal Year 2025 Financial Results on December 17th

    MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, December 17, 2025, at 8:00 a.m. ET to discuss its fiscal year 2025 financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call.

    12/10/25 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LODE
    $VERU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Veru Inc.

    SC 13G/A - VERU INC. (0000863894) (Subject)

    11/12/24 9:34:37 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Veru Inc.

    SC 13G/A - VERU INC. (0000863894) (Subject)

    11/4/24 4:19:00 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Veru Inc.

    SC 13G - VERU INC. (0000863894) (Subject)

    4/24/24 4:16:01 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care